Cover Image

Pharmacotherapy of Alzheimer’s disease: a thorny road to success

Neurodegenerative diseases including Alzheimer disease (AD) and Parkinson disease (PD) are characterized by progressive neuronal loss and pathological accumulation of some proteins. Developing new biomarkers for both diseases is highly important for the early diagnosis and possible development of ne...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibrahim, Nurul Husna, Kumar, Jaya, Mohamed, Wael Mohamed Yousef
Format: Book Chapter
Language:English
Published: Elsevier 2025
Subjects:
R Medicine (General)
Online Access:http://irep.iium.edu.my/115364/7/115364_Pharmacotherapy%20of%20Alzheimer%E2%80%99s%20disease.pdf
http://irep.iium.edu.my/115364/
https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000270?via%3Dihub
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.115364
record_format dspace
spelling my.iium.irep.1153642024-12-04T08:05:53Z http://irep.iium.edu.my/115364/ Pharmacotherapy of Alzheimer’s disease: a thorny road to success Ibrahim, Nurul Husna Kumar, Jaya Mohamed, Wael Mohamed Yousef R Medicine (General) Neurodegenerative diseases including Alzheimer disease (AD) and Parkinson disease (PD) are characterized by progressive neuronal loss and pathological accumulation of some proteins. Developing new biomarkers for both diseases is highly important for the early diagnosis and possible development of neuroprotective strategies. Currently available treatments for AD only improve the disease symptoms but do not treat the underlying pathophysiological processes. Many drugs targeting the production, aggregation, and clearance of ab plaques failed to give any conclusive clinical outcomes. This mainly stems from the fact that AD is not a disease attributed to a single-gene mutation. Emerging treatments targeting neuroinflammation in AD, such as nonsteroidal antiinflammatory drugs (NSAIDs) and receptor-interacting serine/threonine-protein kinase 1 (RIPK1), restore calcium dyshomeostasis and microglia physiological function in clearing Abeta plaques, respectively, will be deliberately discussed. Other novel pharmacotherapy strategies in treating AD, including disease-modifying agents (DMTs), repurposing of medications used to treat non-AD illnesses, and multitarget-directed ligands (MTDLs) are also reviewed. Furthermore, EBN (Edible Bird Nest) is recently used as complementary medicine in treating AD. Elsevier 2025 Book Chapter PeerReviewed application/pdf en http://irep.iium.edu.my/115364/7/115364_Pharmacotherapy%20of%20Alzheimer%E2%80%99s%20disease.pdf Ibrahim, Nurul Husna and Kumar, Jaya and Mohamed, Wael Mohamed Yousef (2025) Pharmacotherapy of Alzheimer’s disease: a thorny road to success. In: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Advances. Elsevier, London, UK, pp. 437-460. ISBN 9780443157028 https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000270?via%3Dihub 10.1016/B978-0-443-15702-8.00027-0
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
spellingShingle R Medicine (General)
Ibrahim, Nurul Husna
Kumar, Jaya
Mohamed, Wael Mohamed Yousef
Pharmacotherapy of Alzheimer’s disease: a thorny road to success
description Neurodegenerative diseases including Alzheimer disease (AD) and Parkinson disease (PD) are characterized by progressive neuronal loss and pathological accumulation of some proteins. Developing new biomarkers for both diseases is highly important for the early diagnosis and possible development of neuroprotective strategies. Currently available treatments for AD only improve the disease symptoms but do not treat the underlying pathophysiological processes. Many drugs targeting the production, aggregation, and clearance of ab plaques failed to give any conclusive clinical outcomes. This mainly stems from the fact that AD is not a disease attributed to a single-gene mutation. Emerging treatments targeting neuroinflammation in AD, such as nonsteroidal antiinflammatory drugs (NSAIDs) and receptor-interacting serine/threonine-protein kinase 1 (RIPK1), restore calcium dyshomeostasis and microglia physiological function in clearing Abeta plaques, respectively, will be deliberately discussed. Other novel pharmacotherapy strategies in treating AD, including disease-modifying agents (DMTs), repurposing of medications used to treat non-AD illnesses, and multitarget-directed ligands (MTDLs) are also reviewed. Furthermore, EBN (Edible Bird Nest) is recently used as complementary medicine in treating AD.
format Book Chapter
author Ibrahim, Nurul Husna
Kumar, Jaya
Mohamed, Wael Mohamed Yousef
author_facet Ibrahim, Nurul Husna
Kumar, Jaya
Mohamed, Wael Mohamed Yousef
author_sort Ibrahim, Nurul Husna
title Pharmacotherapy of Alzheimer’s disease: a thorny road to success
title_short Pharmacotherapy of Alzheimer’s disease: a thorny road to success
title_full Pharmacotherapy of Alzheimer’s disease: a thorny road to success
title_fullStr Pharmacotherapy of Alzheimer’s disease: a thorny road to success
title_full_unstemmed Pharmacotherapy of Alzheimer’s disease: a thorny road to success
title_sort pharmacotherapy of alzheimer’s disease: a thorny road to success
publisher Elsevier
publishDate 2025
url http://irep.iium.edu.my/115364/7/115364_Pharmacotherapy%20of%20Alzheimer%E2%80%99s%20disease.pdf
http://irep.iium.edu.my/115364/
https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000270?via%3Dihub
_version_ 1817841071157149696
score 13.223943

Similar Items